For instance, an NT-proBNP-guided strategy in chronic HF can identify patients who might benefit from more aggressive therapy, although the NT-proBNP alone has limitations (e.g., levels can be affected by renal function, age, or obesity). Here, NPPB is linked to obesity due to melanocortin 4 receptor deficiency.